Again Technologies has acquired Geno, a developer of plant-based materials and ingredients, for an undisclosed amount. The transaction brings Geno’s biotechnology platform and intellectual property portfolio under Again’s ownership, expanding the acquirer’s capabilities in sustainable chemistry.
Geno, formerly known as Genomatica, specializes in using microorganisms and fermentation processes to convert plant sugars into materials and ingredients that traditionally derive from fossil fuels. Its technology spans product pathways, synthetic biology approaches, and bio-manufacturing processes, supported by a portfolio of 2,200 patents and applications. The company has licensed its technology to manufacturers including Novamont, Qore, Covestro, and Aquafil, and has deployed more than $300 million in technology investment over two decades.
Again Technologies focuses on industrial biotechnology, with an emphasis on scaling sustainable production methods. The acquisition gives Again access to Geno’s established research and development infrastructure, including its Innovation Center and team of engineers and scientists. It also adds a mature licensing model and relationships with large industrial partners, which could accelerate the deployment of bio-based alternatives across multiple sectors.
The strategic rationale centers on combining Again’s operational approach with Geno’s proven fermentation and engineering expertise. Geno’s existing product lines and partnerships offer a foundation for expanding production volumes, while its patent estate provides a broad base for future development. The deal is expected to strengthen Again’s position in the market for renewable feedstocks and circular supply chains.
The combined entity will operate with a larger technology stack and a more extensive customer network, potentially enabling faster commercialization of plant-derived materials. Integration of Geno’s team and facilities will be a key near-term focus, with the goal of maintaining continuity for existing licensees while pursuing new applications. The acquisition positions the merged company to compete more directly in the transition toward bio-based industrial inputs.